Abstract
Molnupiravir is a recently approved drug against the ongoing worldwide pandemic of COVID-19. The current study endeavors to identify and characterize the degradation products of molnupiravir using LC-MS/MS for rapid drug development. The HPLC separation was achieved using Waters Xselect HSS T3 (75 × 4.6 mm, 2.5 µm) column with ammonium formate and ACN as mobile phase in gradient elution mode. The injection volume was 5 µL with 0.7 mL/min flow rate. The detection wavelength was 272 nm and all the study was performed at a constant column temperature of 25 °C. MS/MS study of molnupiravir and its DPs was performed at optimized mass parameters and in total four DPs were identified and characterized. The mechanistic pathway of formation of all DPs from molnupiravir is established. Online web server Pro Tox II was used to predict the in-silico safety profile of DPs in comparison to the drug.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Liquid Chromatography & Related Technologies
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
